These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 8004415)

  • 21. Particulate matter in parenteral products: a review.
    Borchert SJ; Abe A; Aldrich DS; Fox LE; Freeman JE; White RD
    J Parenter Sci Technol; 1986; 40(5):212-41. PubMed ID: 3540253
    [No Abstract]   [Full Text] [Related]  

  • 22. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Risk- and Science-Based Approach to the Acceptance Sampling Plan Inspection of Protein Parenteral Products.
    Spasoff A; Bennis A; Atkinson S; Elliott C; Freund E; Narhi L
    J Pharm Sci; 2018 Sep; 107(9):2306-2309. PubMed ID: 29859961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Particle contamination of parenteralia and in-line filtration of proteinaceous drugs.
    Werner BP; Winter G
    Int J Pharm; 2015 Dec; 496(2):250-67. PubMed ID: 26556624
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lyophilization of unit dose pharmaceutical dosage forms.
    Thapa P; Baillie AJ; Stevens HN
    Drug Dev Ind Pharm; 2003 May; 29(5):595-602. PubMed ID: 12779289
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depyrogenation by endotoxin removal with positively charged depth filter cartridge.
    Hou KC; Zaniewski R
    J Parenter Sci Technol; 1990; 44(4):204-9. PubMed ID: 2213428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cleanliness assessment of supplier-cleaned stoppers.
    Townsend MW; Conti B; Hazrati A; DeLuca PP
    J Parenter Sci Technol; 1989; 43(2):98-102. PubMed ID: 2709242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effects of lyophilization on the stability of liposomes containing 5-FU.
    Glavas-Dodov M; Fredro-Kumbaradzi E; Goracinova K; Simonoska M; Calis S; Trajkovic-Jolevska S; Hincal AA
    Int J Pharm; 2005 Mar; 291(1-2):79-86. PubMed ID: 15707734
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticles formulation and its pharmacokinetic profile in rats.
    Yang ZQ; Xu J; Pan P; Zhang XN
    Pharmazie; 2009 Jan; 64(1):26-31. PubMed ID: 19216227
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physico-chemical lyophilization behavior of mannitol, human serum albumin formulations.
    Hawe A; Friess W
    Eur J Pharm Sci; 2006 Jun; 28(3):224-32. PubMed ID: 16580820
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formation of Stable Nanobubbles on Reconstituting Lyophilized Formulations Containing Trehalose.
    Zhou C; Cleland D; Snell J; Qi W; Randolph TW; Carpenter JF
    J Pharm Sci; 2016 Jul; 105(7):2249-53. PubMed ID: 27287517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stability of doripenem in vitro in representative infusion solutions and infusion bags.
    Psathas PA; Kuzmission A; Ikeda K; Yasuo S
    Clin Ther; 2008 Nov; 30(11):2075-87. PubMed ID: 19108795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Studies on the photostability of reserpine in parenteral solutions.
    Jamil N; Afrozrizvi H; Ahmed I; Beg AE
    Pharmazie; 1983 Jul; 38(7):467-9. PubMed ID: 6415678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An approach to setting particulate matter standards for small volume parenterals.
    DeLuca PP; Boddapati S; Haack D; Schroeder H
    J Parenter Sci Technol; 1986; 40(1):2-13. PubMed ID: 3701538
    [No Abstract]   [Full Text] [Related]  

  • 35. Development and validation of HPLC methods for the determination of potential extractables from elastomeric stoppers in the presence of a complex surfactant vehicle used in the preparation of parenteral drug products.
    Xiao B; Gozo SK; Herz L
    J Pharm Biomed Anal; 2007 Jan; 43(2):558-65. PubMed ID: 17049198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Visible particle limits in small volume parenterals.
    Leelarasamee N; Howard SA; Baldwin HJ
    J Parenter Drug Assoc; 1980; 34(3):167-74. PubMed ID: 6901772
    [No Abstract]   [Full Text] [Related]  

  • 37. [Particle contamination of infusion solution and equipment].
    Hübner G
    Klin Anasthesiol Intensivther; 1977; (14):70-3. PubMed ID: 926692
    [No Abstract]   [Full Text] [Related]  

  • 38. [Filter systems for the prevention of material and bacterial contamination].
    Ahnefeld FW; Dick W
    Klin Anasthesiol Intensivther; 1977; (14):131-8. PubMed ID: 926679
    [No Abstract]   [Full Text] [Related]  

  • 39. Recommendations to pharmacists for solving problems with large-volume parenterals-1979. National Coordinating Committee on Large Volume Parenterals.
    Am J Hosp Pharm; 1980 May; 37(5):663-7. PubMed ID: 7386474
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
    Van der Schoot SC; Nuijen B; Sood P; Thurmond KB; Stewart DR; Rice JR; Beijnen JH
    Pharmazie; 2006 Oct; 61(10):835-44. PubMed ID: 17069422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.